🔴 Goodrx is trading 5% down in after-hours trading after flagging unreliable Q1 and Q2 2026 statements

Goodrx is trading at $3.30, down 5.44% in after-hours trading after saying its Q1 and Q2 2026 financial statements should no longer be relied upon.

• The issue was understated Pharma Direct revenue. Goodrx plans to restate the results; preliminary adjustments increase reported revenue, but the review is ongoing.
• Goodrx expects to report one or more material weaknesses in internal controls for the affected periods. It filed the disclosure with the SEC on November 2, ahead of the November 3 after-hours move.